ArticleWorld journal of clinical cases2024

Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab: A case report.

Xuan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.